Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib

Author:

Cheah Chan Y.12,Burbury Kate12,Apperley Jane F.3,Huguet Francoise4,Pitini Vincenzo5,Gardembas Martine6,Ross David M.789,Forrest Donna10,Genet Philippe11,Rousselot Philippe12,Patton Nigel13,Smith Graeme14,Dunbar Cynthia E.15,Ito Sawa15,Aguiar Ricardo C. T.1617,Odenike Olatoyosi18,Gimelfarb Alla19,Cross Nicholas C. P.20,Seymour John F.12

Affiliation:

1. Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia;

2. University of Melbourne, Parkville, VIC, Australia;

3. Department of Haematology, Faculty of Medicine, Imperial College London, London, United Kingdom;

4. Department of Haematology, Centre Hospitalier Universitaire, Toulouse, France;

5. Oncologia Medica e Trapianto di Midollo Osseo, Messina, Italy;

6. Department of Haematology, Centre Hospitalier Universitaire, Angers, France;

7. Haematology, South Australia Pathology, Adelaide, SA, Australia;

8. School of Medicine, University of Adelaide, Adelaide, SA, Australia;

9. School of Medicine, Flinders University, Adelaide, SA, Australia;

10. British Columbia Cancer Agency, Vancouver, BC, Canada;

11. Department of Haematology, Hôpital Victor Dupouy, Argenteuil, France;

12. Department of Haematology, Hôpital de Versailles and Université de Versailles Saint-Quentin, Le Chesnay, France;

13. Department of Haematology, Auckland City Hospital, Auckland, New Zealand;

14. Department of Haematology, St. James’s University Hospital, Leeds, United Kingdom;

15. Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD;

16. Department of Medicine, University of Texas Health Science Center, San Antonio, TX;

17. Audie Murphy Veterans Affairs Hospital, San Antonio, TX;

18. Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL;

19. Northshore University Health Systems, Chicago, IL;

20. Faculty of Medicine, University of Southampton, Southampton, United Kingdom

Abstract

Key Points Imatinib achieves deep and durable remissions in patients with myeloid neoplasms bearing PDGFRB. Allogeneic stem cell transplantation is no longer indicated for patients with chronic myeloproliferative neoplasm bearing PDGFRB who respond to imatinib.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3